The pathway by which the chordates evolved from lower animal groups remains elusive [1, 2] . Recently, molecular evidence has shed light on the problem, suggesting that chordates share a common body plan with articulates (arthropods and annelids); that notoneuralian chordates may have inverted their dorsoventral body axis while evolving from a gastroneuralian ancestor [3, 4] ; and that insect and vertebrate brains and nerve cords are built according to a common ground plan [5] . Here, we propose that enteropneusts (acorn worms, hemichordata), a putative sister group of the chordates, may link invertebrates with dorsoventrally inverted chordates, and that their ventral trunk cord may correspond to the nerve cords of both articulates and chordates.
Enteropneusts have in their trunk region a dorsal and a ventral concentration of nerve cells that both converge anteriorly into the dorsal collar cord (Fig. 1) . In the collar cord, the epidermis and associated nerve cells form a tube that has been compared to the dorsal neural tube in chordates [6] . Interestingly, giant nerve cells that reside in the dorsal collar cord project their giant fibres, via a prebranchial circumenteric nerve ring, into the ventral -and not into the dorsal -trunk cord [7, 8] , and the ventral trunk cord is about twice as thick as its dorsal counterpart [6, 7] . In line with this, severing the dorsal trunk cord does not prevent the animal's retreat response to an anterior stimulus, whereas a cut across the ventral trunk cord does [7] . It thus appears that the enteropneust dorsal collar cord plus ventral trunk cord form the system controlling locomotor patterns, as do the ventral nerve cord in articulates and the dorsal nerve cord in chordates.
The only spontaneously active nervous centre in enteropneuststheir putative brain -is contained in the proboscis [7] . Hence, in enteropneusts, a ventral nerve cord is connected, via a circumenteric nerve ring, to the dorsoanterior brain, as is the case in gastroneuralian articulates (Fig. 1) . Assuming that articulate and chordate nerve cords and brains represent homologous structures [3, 5] , the same homology could hold for the enteropneust brain plus ventral nerve cord. If this is the case, then the conventional ventral side of enteropneusts should correspond to the dorsal side of chordates. This is in contrast to the current view [2, [9] [10] [11] .
Interestingly, various additional features appear also to be dorsoventrally interchanged between conventionally oriented enteropneusts and chordates: for example, the hepatic structures and the direction of blood flow ( One major problem is evident. In chordates, the mouth opens -given their dorsoventral inversion -to their former dorsal side (Fig. 1) . We have suggested that the chordate mouth is a new mouth, with the old mouth having been obliterated [3] [4] [5] .
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Figure 1
Comparison of the generalized body plans of an annelid, an enteropneust and a chordate, with the chordate turned upside down. The direction of blood flow (arrows) and the relative positions of the gut (green), the principal nerve cord (yellow) and the chordate notochord and enteropneust pygochord (brown) are the same. Similarly, the paired hepatic outpockets in the enteropneust lie in a region comparable to the typhlosole (t) in the annelid and to the liver in the chordate (dark green). Note that the proposed homology between the enteropneust stomochord (s) and the chordate notochord [14] has been contested repeatedly [2, 10, 11] . The arrowhead indicates the position of the mouth in the putative gastroneuralian ancestor of chordates; note that the functional mouth of the chordate is a new mouth (see [3, 4] In accordance with this interpretation, the anlage of the enteropneust and chordate mouths map to opposite sides of the brain rudiment [2] , with the anlage of the enteropneust mouth corresponding to the proposed location of the obliterated mouth in chordates [3] [4] [5] .
So, if one equates the conventional ventral side of enteropneusts with the dorsal side of the chordates, then in both body plans the brain plus (principal) nerve cord, as well as the pygochord or notochord, the direction of blood flow and the hepatic structures coincide (Fig. 1) 
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Biogen, Inc.
What is it famous for? Being one of the first biotechnology companies, and the oldest one still to be independent.
How did it start? It was founded in 1978 by an international group of scientific luminaries, including Phillip Sharp, Kenneth Murray and Walter Gilbert. Sharp is currently chairman of the scientific board.
Does it actually sell any products?
Not yet. Like most biotechnology firms, Biogen started out by licensing its most promising products to larger firms in return for royalties on sales.
Interferon-␣ was licensed to Schering-Plough, and recombinant hepatitis B antigens, used for vaccines, were licensed to SmithKline Beecham and to Merck. But Biogen should soon start to market a product of its very own, interferon-␤1A.
What is interferon-␤1A good for? In December 1995, an advisory committee recommended the US Federal Drug Agency approve its use as a treatment for relapsing forms of multiple sclerosis (MS). In a Phase III trial, treatment with the drug reduced the progression of patients with MS by 40 % -by an unknown mechanism.
What else is it working on? Most of the products in preclinical or early clinical development are immunosuppressants: for example, an antibody to VLA-4 which should stop lymphocyte traffic through blood vessel walls, and an engineered antibody-like molecule that seems to inhibit T-cell proliferation.
Does the company make a profit?
Usually. In 1993, it made a profit of $32.4 million, in 1994 a loss of $4.9 million, and in 1995 a profit again, to the tune of $5.6 million. The main reason for the loss in 1994 was a cost of $25 million for stopping work on Hirulog, a leech-derived thrombin inhibitor, after a Phase III trial showed that it was no better than heparin at preventing clot formation.
Where do the profits go? Some are reinvested, some go to individuals, and some are funnelled into the academic community. For example, royalties paid to Kenneth Murray for work on hepatitis B have been donated to Edinburgh University and the Darwin Trust, providing funds for a new library, a biological sciences building, graduate students and postdoctoral fellows.
How does it compare with other biotechnology companies? As a profitmaking company, however erratic, Biogen probably rates as one of the top five biotechnology companies. At around 500 employees, it doesn't compare in size with Amgen or Genentech, but there aren't many other larger biotech companies.
How much does it put into research?
In 1995, Biogen's total revenues were $151.7 million, of which $87.4 million was spent on research and development. R & D staff number 186; Biogen currently employs 88 PhDs and MDs in total. The expectation of new revenues from interferon-␤1A sales has triggered a hiring frenzy in all parts of the company; jobs on offer can be found on Biogen's web site (http://www. careermosaic.com/cm/biogen/).
